Journal of Cutaneous Medicine and Surgery最新文献_第9页

Vulvar Condyloma Lata. Vulvar Condyloma Lata报道。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2025-01-27 DOI: 10.1177/12034754241311278

Chandana Shajil, H Shatikkulamin

引用次数: 0

Biologic Therapy in Psoriasis Patients with Renal Disease: A Systematic Review. 肾病银屑病患者的生物疗法：系统回顾。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2024-10-25 DOI: 10.1177/12034754241293085

Ryan S Q Geng, Siddhartha Sood, Jihad Waked, Nabil Merchant, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti

引用次数: 0

Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada. 加拿大 Tildrakizumab 治疗中重度斑块状银屑病的实际效果。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2024-12-14 DOI: 10.1177/12034754241302827

Mohannad Abu-Hilal, Jeff Cowger, Mohammed Bawazir, Dusan Sajic, Iryna Savinova, Belinda Yap, Rami El-Sayegh, Talshyn Bolatova, Pak Chan, Ajith Cy

{"title":"Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada.","authors":"Mohannad Abu-Hilal, Jeff Cowger, Mohammed Bawazir, Dusan Sajic, Iryna Savinova, Belinda Yap, Rami El-Sayegh, Talshyn Bolatova, Pak Chan, Ajith Cy","doi":"10.1177/12034754241302827","DOIUrl":"10.1177/12034754241302827","url":null,"abstract":"Background: Tildrakizumab is an interleukin-23 inhibitor approved in Canada in 2021 for the treatment of adults with moderate-to-severe plaque psoriasis.Objectives: To evaluate real-world effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Canada.Methods: A multicenter, retrospective study was conducted in Canada in adults with moderate-to-severe plaque psoriasis for ≥1 year treated with tildrakizumab for ≥12 weeks. Effectiveness was evaluated from proportions of patients achieving ≥75%/≥90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 75/90/100 response) and Physician Global Assessment (PGA) 0 or 1 at weeks 16 (±4), 24 (±8), and 48 (±12). Subgroup analyses were performed based on prior biologic use and special site involvement.Results: The study included 75 patients (mean age, 50.5 years; 52.0% female; 82.7% bio-naïve; 73.3% with special site involvement). Absolute mean (standard deviation) PASI score improved from 16.1 (6.7) at baseline to 1.3 (1.7) at the week 48 (91.7% improvement), 95.7%/69.6%/34.8% of patients achieved PASI 75/90/100 response, and 93.0% achieved PGA 0/1 at the week 48. In subgroup analyses, 94.7%/71.1%/34.2% of bio-naïve patients, 100.0%/62.5%/37.5% of bio-experienced patients, 100.0%/71.4%/28.6% of patients with special site involvement, and 81.8%/63.6%/54.6% of patients without special site involvement achieved PASI 75/90/100 response, and 87.5%, 94.3%, 97.0%, and 80.0% of patients, respectively, achieved PGA 0/1 at the week 48. None of the differences among subgroups were statistically significant; however, patient numbers were too small to support robust conclusions.Conclusions: Tildrakizumab is effective for the treatment of moderate-to-severe plaque psoriasis in adults in a real-world setting in Canada.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"137-142"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Squamous Cell Carcinoma Within Vulvar Lichen Sclerosus. 外阴硬化地衣内的鳞状细胞癌。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1177/12034754241308258

Vishal Gaurav, Gaby Lalmuanpuii

引用次数: 0

Tocilizumab for the Treatment of Refractory Morphea: A Systematic Review. 托西珠单抗治疗难治性斑秃：系统综述。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2024-10-25 DOI: 10.1177/12034754241291045

Dea Metko, Shanti Mehta, Ryan Geng, Asfandyar Mufti, Jensen Yeung

引用次数: 0

The Prevalence of Hidradenitis Suppurativa in Calgary, Alberta, Canada: Results from a Participating Site in the Global Hidradenitis Suppurativa Atlas Cross-Sectional Study. 加拿大阿尔伯塔省卡尔加里化脓性汗腺炎的患病率：来自全球化脓性汗腺炎地图集横断面研究的一个参与地点的结果。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-03-01 Epub Date: 2024-11-29 DOI: 10.1177/12034754241303060

Leah A Johnston, Susan M Poelman, Dorra Bouazzi, Jurr Boer, Gregor Borut Ernst Jemec

引用次数: 0

Clinical Characteristics and Treatment Outcomes of Reported Cases of Non-Cutaneous Melanomas: A Systematic Review. 非皮肤黑色素瘤病例的临床特征和治疗结果：系统回顾。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-02-28 DOI: 10.1177/12034754251324943

Edgar Akuffo-Addo, Sinthiha Krishnan, Ennie Olajide, Eunice Aluko, Lea Saroufim, Ezekiel Garuba, Nana Efia Acquah, Katya Peri, Angel Osei, Robin Olaonipekun, Ebenezer Oladogba, Ilya Mukovozov

引用次数: 0

Patterns of Pediatric Chronic Hand Eczema: A Systematic Review with Focus on Causes and Management. 儿童慢性手湿疹的模式：一个系统的回顾，重点是原因和管理。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-02-26 DOI: 10.1177/12034754251322883

Katie C Y Yeung, Joshua Lowe, Jessica S S Ho, Sonja Molin

{"title":"Patterns of Pediatric Chronic Hand Eczema: A Systematic Review with Focus on Causes and Management.","authors":"Katie C Y Yeung, Joshua Lowe, Jessica S S Ho, Sonja Molin","doi":"10.1177/12034754251322883","DOIUrl":"https://doi.org/10.1177/12034754251322883","url":null,"abstract":"Chronic hand eczema (CHE) is commonly seen in adults and often in the context of occupational exposures. Recently, there has been a growing number of cases reported among children. We conducted a systematic review using the PRISMA framework to identify cases of pediatric CHE. Search terms included \"eczema,\" \"dermatitis,\" \"pompholyx,\" \"dyshidrosis,\" \"contact allergy,\" and \"pulpitis.\" Case reports of patients aged <18 years old without an alternate/confounding diagnosis were included. 62 cases were included with a mean age of 10.9 years. In the patients with reported data, 61% (28/46) had a history of atopy and 38% (14/37) reported lesions were present for >1 year. The most common cause was allergic-contact dermatitis (71%) with the bilateral hands affected (87%). A total of 35 unique triggers were identified, with the top 5 being homemade slime (n = 28), store-bought slime (n = 8), outdoor plants (n = 4), UV-curing methacrylate nail polish (n = 4), and sporting gloves (n = 4). Patch testing was performed in 87% (54/62) of patients, of which 96% (52/54) tested positive to 1+ allergens. Positive reactions to methylchloroisothiazolinone and/or methylisothiazolinone (MCI/MI) were among the most common. In 53% (33/62) of patients, removal of the trigger resulted in resolution. Patterns of CHE triggers in pediatric patients differ from adults, and workup should include a detailed history of leisure-time and school activities. MCI/MI was the most common culprit, and trends involving children making slime has led to an increase in prolonged/repeated exposure. Awareness of potential causes ensures early identification, patch testing, prompt removal of trigger, and appropriate management.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251322883"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon. 白癜风：发病机制和治疗的综述，包括新疗法的前景。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-02-26 DOI: 10.1177/12034754251320637

Catalina Retamal, Dan Hartmann, Fernando Valenzuela

{"title":"Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon.","authors":"Catalina Retamal, Dan Hartmann, Fernando Valenzuela","doi":"10.1177/12034754251320637","DOIUrl":"https://doi.org/10.1177/12034754251320637","url":null,"abstract":"Vitiligo is an acquired depigmentation skin disease caused by the immune-mediated death of melanocytes. It is the most common cause of depigmentation with an estimated worldwide prevalence of 1% but has shown insufficient response to current therapies. The latest research in vitiligo pathogenesis has translated into finding new molecular targets [type I interferon and Janus kinase signal transducers and transcription activators (JAK STAT) pathways], with new therapies generating promising results, such as JAK inhibitors. Other therapeutic strategies include phototherapy, surgical treatment, and complementary options such as micropigmentation, microneedling, and lasers. This review aimed to discuss the mechanisms involved in the development of the disease and the new therapeutic options that have become available, as well as the evidence on complementary therapies. For this purpose, a review of the evidence was conducted using the PubMed database. Based on this review, it was concluded that the progress in understanding the pathophysiology of vitiligo has allowed for the consideration of new molecular targets, with JAK inhibitors showing particular promise in both systemic and topical applications. Nonetheless, further investigation is required to assess the safety of JAK inhibitors and to determine the optimal regimen and dosage for administering these drugs. Complementary treatments should be considered on a case-by-case basis.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251320637"},"PeriodicalIF":3.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isotretinoin for the Management of Classic Lichen Planopilaris: A Systematic Review. 异维A酸治疗经典平栉地衣的系统综述。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-02-26 DOI: 10.1177/12034754251320646

Aliyah King, Carly Kirshen, Marcus G Tan

引用次数: 0